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Antibody mediated therapeutic strategies against human malignant tumors have been widely authorized and clinically applied
to cancer patients. In order to develop methods to generate antibodies reactive to the extracellular domains of multipass plasma
membrane proteins speciﬁcally expressed in malignant tumors, we examined the use of dendritic cells (DCs) for immunization.
DCs were transduced with genes encoding the human six transmembrane epithelial antigen of prostate 1 (STEAP1), STEAP4, and
seven transmembrane prostate speciﬁc G-protein coupled receptor (PSGR). Mice were immunized with these DCs and followed
by repeated booster immunization with plasmids expressing each protein. The immunized mice produced signiﬁcant amounts of
antibodies against these proteins. Our results suggest that DC immunization is an eﬀective method to produce antibodies reactive
to extracellular regions of plasma membrane proteins with multiple-transmembrane domains, and may be useful to develop
antibody mediated antitumor therapies.
Copyright © 2009 T. Tamura and J. Chiba. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
In the development of antibody-mediated therapies targeted
to human cancer cells, including cancer stem/progenitor
cells, the extracellular domains of plasma membrane pro-
teins speciﬁcally expressed on cancer cells are promising
candidates for antigens against which to be immunized [1],
but the high homology of amino acid sequences between
human antigens and their homologues in animals to be
immunized often hamper eﬃcient antibody production
because of immunological tolerance. In the case of cellular
membrane proteins having only a single transmembrane
domain, recombinant protein with the extracellular domain
fused to the Ig-Fc domain has been used as immunogen in
many cases to generate antibodies reactive with the extracel-
lular region [2]. However, in the case of plasma membrane
proteins having multiple transmembrane domains, the three
dimensional architecture of the protein outside the cell is
expected to be composed of multiple extracellular domains,
suggesting that construction of Ig-Fc fusion proteins for
immunization would be diﬃcult.
To obtain antibodies reactive to the native extracellu-
lar structure of such membrane proteins, immunization
by injection of cultured cells expressing the antigen has
been used [3]. However, large numbers of cells (typically
107-108 cells per animal) are usually needed to prepare for
immunization and some modiﬁcations of the injected cells
are required, for example, genes encoding immunomodula-
tory cytokines (interleukin-4, and others) or costimulatory
molecules are expressed together with the antigen to obtain
higher titers. Moreover, the cells expressing plasma mem-
brane proteins having multiple transmembrane domains
such as G-protein coupled receptors (GPCRs) are not
always available for immunization. Therefore, development
of a simple and successful protocol for immunization
against human multi-pass membrane proteins is needed in
antibody-mediated cancer research.
Dendritic cells (DCs) are the most potent antigen
presenting cells and robustly induce adaptive immunity
mediated by T cells and B cells [4, 5]. The central role of
DCs in immunity may explain why DC-mediated vaccines
have been used for induction of cellular immunity against2 Journal of Biomedicine and Biotechnology
malignant tumor cells and infectious pathogens [6–8]. The
potency of DCs was demonstrated in previous studies to
disrupt immunological tolerance against a tumor antigen
and induce tumor antigen speciﬁc T cells [9]. In addi-
tion, DCs also play a key role in induction of humoral
immunity [10]. The activation of CD4+ T cells by DCs
can exert helper functions to enhance eﬃcient antibody
production, production of high-aﬃnity antibodies through
somatic hypermutation, and class-switching of antibodies.
DCs can also release exosomes containing intact antigen,
which induces activation of antigen speciﬁc B cells antibody
responses [11]. These observations strongly suggest that tar-
geted expression of antigens in DCs to stimulate production
of useful antibodies is a reasonable experimental approach;
however, such attempts have been limited [9, 12].
In this study, we focused on an immunization method
using DCs expressing human tumor transmembrane anti-
gens. DCs can eﬃciently present antigen to B cells and
CD4+ T cells because DCs express the antigen in intact
form on the cell surface, to be recognized by antigen-
reactive B cells, and in processed form in context with MHC
molecules, to be speciﬁcally recognized by CD4+ T cells.
These properties may oﬀer many advantages in eﬃcient
generation of antigen-speciﬁc antibodies. The antigens used
for immunization in this study were the human six trans-
membrane epithelial antigen of prostate 1 (STEAP1), human
STEAP4, and the human prostate speciﬁc G-protein coupled
receptor (PSGR) [13–17]. These antigens possess multiple
transmembrane domains (6 in STEAPs and 7 in PSGR) and
high degree of homology with the corresponding mouse
proteins (82% in STEAPs and 92% in PSGR amino acid
identity between human and mouse). The complex native
extracellular structures and their high degree of homology
imply that production of antibodies against such membrane
proteins may be diﬃcult. However, in this study, we show
that immunization using DCs eﬃciently induced antibody
production against these membrane proteins in mice, which
could be used for antibody-mediated immunological assays,
including ﬂow cytometry, immnuoﬂuorescent staining, and
Western blotting.
2.MaterialsandMethods
2.1. Mice. BALB/C mice (6–8 weeks old) were purchased
from Sankyo Labo Service Co. (Tokyo, Japan). All animal
experiments were performed according to the guidelines of
the Tokyo University of Science.
2.2. Cell Culture. 293T cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with
10% heat inactivated fetal calf serum (FCS). PlatE cells
were cultured in DMEM supplemented with 10% heat
inactivated FCS, blasticidin (10μg/mL) and puromycin
(2μg/mL). LNCaP and DU145 human prostate cancer cell
l i n e sw e r ep u r c h a s e df r o mR I K E NB i o R e s o u r c eC e n t e r
(Tsukuba, Japan) and cultured in RPMI 1640 supplemented
with 10% heat inactivated FCS. For androgen stimulation, 5-
α-dihydrotestosterone (5-DHT) was purchased from Wako
Pure Chemical Industries (Osaka, Japan).
2.3. Generation of Mouse Bone Marrow Derived Dendritic
Cells (BM-DCs). The culture of BM-DCs has been previ-
ously described [18]. Brieﬂy, bone marrow cells from tibias
and femurs of BALB/C mice were isolated, and 2 × 106 cells
were plated in 10 cm bacterial dishes (IWAKI, Chiba, Japan)
and cultured in RPMI 1640 supplemented with 10% heat
inactivatedFCSand20ng/mLrecombinantmurineGM-CSF
(Peprotech, Rocky Hill, NJ) for 10 days. The suspension and
loosely-adherentcellswerecollectedasCD11b
+CD11c+ BM-
DCs.
2.4. Construction of Expression Vectors. pCAGGS, and
pCAGGS-HA containing cDNA encoding hemagglutinin
(HA) of human inﬂuenza A virus (H1N1/PR8) was kindly
provided by Dr. H. Hasegawa (National Institute of Infec-
tious Diseases, Japan). The cDNA encoding human STEAPs
(STEAP1 and STEAP4) and human PSGR were cloned from
human spleen cDNAs (Clontech, Palo Alto, CA) using PCR
and from human prostate RNA (Clontech) using RT-PCR,
respectively. PCR products were inserted into pGEM T-easy
vector (Promega, Madison, WI). The sequences of these
cDNA fragments were conﬁrmed using ABI Prism 3100-
Avant DNA sequencer (Applied Biosystems, Foster City,
CA). The cDNAs were excised from pGEM T-easy vector
and inserted into either pMRX-IRES-GFP or pCAGGS. The
plasmids were propagated in E. coli (DH5α) and puriﬁed
using a kit (QIAGEN, Valencia, CA) for the following
experimental procedures.
2.5. The Infection of BM-DCs with a Retroviral Vector. PlatE
cells in 10cm dishes were transfected with pMRX-hSTEAP1
(hSTEAP4, hPSGR)-IRES-GFP using Fugene 6 (Roche, Indi-
anapolis, IN). The collected culture supernatants were added
to BM-DC cultures on days 4 and 8 and incubated with
5μg/mL polybrene (Sigma, St. Louis, MO) overnight. The
medium was replaced by fresh medium after the overnight
incubation. On day 10, BM-DCs were collected and analyzed
using FACSCalibur (Becton Dickinson, San Jose, CA) to
conﬁrm GFP expression in BM-DCs. The percentage of
GFP positive cells in BM-DCs was routinely 1–5% and the
phenotype of the GFP positive BM-DCs was as same as non-
infected BM-DCs.
2.6. The Immunization Protocol. The BM-DCs (2 × 106
cells/mouse) were injected via tail vein or directly into
the spleen of mice (0 weeks). At 2 weeks, 4 weeks, and
6 weeks, gene transduction with plasmids expressing anti-
gens (pCAGGS-hSTEAP1, -hSTEAP4, and -hPSGR; 5μgo f
plasmids/mouse) was performed as a booster immunization
using hydrodynamic delivery via the tail vein [19]. The
sera at 8 weeks after DC injection were tested in following
immunological assays.
2.7. Flow Cytometry Analysis. 293T cells were transfected
with pMRX-hSTEAP1-IRES-GFP or pMRX-hSTEAP4-
IRES-GFP using Lipofectamine LTX (Invitrogen, Calsbad,
CA). Transfected 293T cells, LNCaP cells, and DU145 cells
were detached from the dish by treatment with PBS/10mM
EDTA, collected, and resuspended in PBS/0.5% bovineJournal of Biomedicine and Biotechnology 3
serum albumin (BSA). The immunized sera (1:100 diluted)
were added to cells, followed by incubation on ice for
30 minutes. After washing, cells were incubated with PE
conjugated goat antimouse IgG (Beckman Coulter, Miami,
FL) and incubated on ice for 30 minutes. After washing,
stained cells were measured using FACSCalibur and data
analysiswasperformedusingtheCellQuestsoftware(Becton
Dickinson). To determine IgG1/2a ratio, the immunized
sera are added to 293T cells transfected with pCAGGS-HA,
followed by incubation on ice for 30 minutes. After washing,
cells were incubated with PE conjugated goat antimouse
IgG1 or IgG2a (Beckman Coulter). The mean ﬂuorescence
intensity of the stained cells was determined and IgG1/2a
ratio was calculated.
2.8. Western Blotting. The proteins in cell lysates were
separated by SDS-PAGE and transferred to Immobilon
membranes (Millipore, Bedford, MA). The Block-Ace (Snow
Brand Milk Products, Tokyo, Japan) solution was used for
blocking the membranes, and membranes were then reacted
with 1:500 diluted anti-STEAP1 serum for 1 hour at room
temperature. After washing, the membranes were incu-
bated with alkaline phosphatase conjugated goat antimouse
IgG+M (Biosource, Camarillo, CA). Reactive bands were
visualized using an NBT/BCIP substrate solution.
2.9. Anti-STEAP4 Monoclonal Antibody Production. Spleen
and bone marrow cells removed from an immunized mouse
were fused with SP2/0 myeloma cells using PEG. The fused
cells were seeded in 96 well plates and cultured in HAT
medium. Positive wells were identiﬁed by ELISA screening.
Hybridoma cells producing anti-hSTEAP4 antibodies were
cloned and established by limiting dilution and ELISA
screening. The immunogloblin class of the antibodies pro-
duced from the hybridoma cells was determined using
IsoStrip mouse monoclonal antibody isotyping kit (Roche).
2.10. Immunoﬂuorescent Staining. LNCaP and transfected
293T cells were seeded in eight-well chamber slides (Nalge-
Nunc, Naperville, IL). The cells were ﬁxed with 3%
paraformaldehyde and, when required, permeabilized with
0.1%TritonX-100for20minutesatroomtemperature.After
blocking, cells were incubated with 1:100 diluted serum or
4F2 (anti-STEAP4 monoclonal antibody) for 1 hour at room
temperature. After washing, cells were incubated with FITC
conjugated goat antimouse IgG (Jackson Immunoresearch,
WestGrove,PA)for1houratroomtemperature.Thestained
cells were observed by confocal microscopy (LSM510, Carl
Zeiss, Jena, Germany). In some cases, 293T cells transfected
with pCAGGS-hSTEAP4 were cultured in regular medium
for 30 minutes in the presence of 4F2. After culturing,
medium was removed and the cells were washed by PBS,
ﬁxed and stained with FITC conjugated antimouse IgG.
3. Results
3.1. STEAP1 Immunization. We immunized mice with DCs
expressing hSTEAP1. After 3 booster injections of pCAGGS-
hSTEAP1, sera from immunized mice were subjected to ﬂow
cytometry analysis to check antibody production against
native extracellular structureof hSTEAP1. The sera from two
of the ﬁve immunized mice reacted with 293T cells express-
ing hSTEAP1 in a ﬂow cytometry analysis (Figure 1(a)).
As negative controls, we also immunized mice with DC
not expressing hSTEAP1 with booster injections, or the
hydrodynamic injections only (N = 3f o re a c hg r o u p ) .
No sera from these negative control groups stained 293T
cells expressing hSTEAP1 (Figure 1(a)). The highest titer of
anti-STEAP1 antibodies by ﬂow cytometry analysis was 900.
Moreover, immunized sera clearly reacted with hSTEAP1
protein (34kd) in Western blotting, but negative control
sera did not (Figure 1(b)). The previous studies [13, 17]
demonstrate that human prostate cancer cell lines including
LNCaP and DU145 express hSTEAP1 endogenously. Flow
cytometry analysis showed that LNCaP cells were signiﬁ-
cantly stained with immunized serum, although DU145 cells
stained very faintly (Figure 1(c)). These results demonstrate
that immunized sera could react with STEAP1 in human
prostate cancer cells. Collectively, DC immunization can
induce production of antibodies reactive to the native
extracellular domain of hSTEAP1.
3.2. STEAP4 Immunization. The frequency of antibody
production against hSTEAP1 was relatively low; therefore,
we investigated better administration routes for DC immu-
nization of mice. We found that intrasplenic injection of
DCs increased the frequency of antibody production relative
to intravenous injections of DCs in HA and hSTEAP1
immunizations (data not shown). Thus, we immunized
mice with hSTEAP4 expressing DCs using intrasplenic
injection.Theimmunizedseraclearlyreactedwith293Tcells
expressing hSTEAP4 in ﬂow cytometry (Figure 2(a)). Sera
from all ﬁve immunized mice exhibited positive staining.
In contrast, booster immunizations (by the hydrodynamics
method) without DC injection of three mice resulted in no
staining in sera from two mice and weak staining in serum
fromonemouse,suggestingthatDCimmunizationiscritical
for eﬃcient antibody generation against hSTEAP4, as well as
hSTEAP1 (Figure 2(a)). The highest titer of anti-STEAP4 by
ﬂow cytometry analysis was 2700. The anti-hSTEAP1 serum
did not react with 293T cells expressing hSTEAP4, and vice
versa, demonstrating that there was no signiﬁcant cross-
reactivity between the hSTEAP1 and hSTEAP4 antibodies
(Figure 2(b)).
A previous study showed that hSTEAP4 was expressed
in LNCaP cells and increased upon androgen stimulation
of the cells [16]. The hSTEAP4 immunized sera stained a
smallproportion (∼1%) ofLNCaPcellsandstaining inthese
cells increased following androgen (5-DHT) treatment of
the cells (Figure 2(c)). The restricted expression of hSTEAP4
in LNCaP cells was also conﬁrmed using immunoﬂorescent
staining (Figure 2(d)). As a negative control, serum from
mice immunized with DCs expressing HA as an irrele-
vant antigen was used, and only background staining was
detected.
Three IgG monoclonal antibodies (one was IgG1, κ
and two were IgG2a, κ) against hSTEAP4 were generated
from an immunized mouse. In immunoﬂuorescent staining,4 Journal of Biomedicine and Biotechnology
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Figure 1: hSTEAP1 immunization. (a) Flow cytometry analysis to detect anti-hSTEAP1 in sera from immunized mice. Upper panels,
DC-STEAP1 immunized (left), preimmunized (right). Lower panels, DC-empty immunized, with booster immunization (left), booster
immunization only without DC immunization (right). 293T cells transiently transfected with pMRX-hSTEAP1-IRES-GFP were stained
with sera, followed by PE conjugated antimouse IgG. (b) Western blotting analysis of hSTEAP1 immunization. The lysates of 293T cells and
293T cells transfected with pCAGGS-hSTEAP1 were probed with serum from immunized mice. (c) Anti-hSTEAP1 ﬂow cytometry analysis
in human prostate cancer cells. From left to right: LNCaP, DU145, and 293T cells. Solid line: anti-STEAP1 serum. Dashed line: preimmune
serum.Journal of Biomedicine and Biotechnology 5
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Figure 2: hSTEAP4 immunization. (a) Flow cytometry analysis to detect anti-hSTEAP4 in sera from immunized mice. 293T cells transiently
transfected with pMRX-hSTEAP4-IRES-GFP were stained with sera, followed by PE conjugated antimouse IgG. (b) Speciﬁc binding of
anti-STEAP antibody in ﬂow cytometry analysis. The upper panels show 293T cells transfected with pMRX-hSTEAP1-IRES-GFP. The
lower panels show 293T cells transfected with pCAGGS-hSTEAP4-IRES-GFP. The cells were reacted with the indicated serum and stained
with PE conjugated antimouse IgG. (c) Detection of hSTEAP4 expression in LNCaP cells using ﬂow cytometry analysis. For androgen
treatment, LNCaP cells were cultured with 5-DHT (10
−9 M) for 24 hours. (d) hSTEAP4 expression in androgen stimulated LNCaP cells
using immunoﬂuorescent staining. Arrow indicates a stained cell. Scale bar = 20μm. (e) hSTEAP4 proteins detected by anti-hSTEAP4
monoclonal antibody (4F2; IgG2a) in 293T cells transfected with pCAGGS-hSTEAP4. Scale bar = 20μm. (f) Anti-hSTEAP4 monoclonal
antibody bound to hSTEAP4 proteins on cell surface. The antibody (4F2) was added to 293T cells transfected with pCAGGS-hSTEAP4 and
the cells continued to be cultured for 30 minutes. The cells were ﬁxed and reacted with FITC conjugated antimouse IgG. Scale bar = 20μm.Journal of Biomedicine and Biotechnology 7
hSTEAP4 proteins were clearly detected in 293T cells
transfectedwithpCAGGS-hSTEAP4usingthesemonoclonal
antibodies as well as the immunized serum (Figure 2(e)).
In Figure 2(e),4 F 2( I g G 2 a )w a su s e da sr e p r e s e n t a t i v e .T h e
stained images demonstrated that hSTEAP4 was localized
on the plasma membrane as well as intracellular structures,
possibly endoplasmic reticulum, endosomes, and Golgi
apparatus, as described previously [16]. Importantly, anti-
STEAP4 monoclonal antibody (4F2) reacted with 293T
cells transfected with pCAGGS-hSTEAP4 even without cell
permeabilization treatment. The stained images showed
extracellular domain of STEAP4 proteins on plasma mem-
brane was recognized by anti-STEAP4 monoclonal antibody.
Moreover, anti-STEAP4 monoclonal antibody (4F2) was
added to 293T cells transfected with pCAGGS-hSTEAP4
followedbyimmunoﬂuorescentstaining. Figure 2(f)showed
that anti-STEAP4 monoclonal antibody bound hSTEAP4
proteins on cell surfaces, suggesting that monoclonal
antibody recognized the native extracellular domains of
hSTEAP4. These results collectively suggest that antibodies
speciﬁc for hSTEAP4 can be eﬃciently generated using DC
mediated immunization.
3.3. PSGR Immunization. We demonstrated that DC immu-
nization signiﬁcantly induced antibody production against
STEAP family proteins. These results prompted us to
investigate whether DC immunization with hydrodynamics
booster injections is applicable to other plasma membrane
proteins. PSGR belongs to the olfactory receptor family and
is an orphan GPCR speciﬁcally expressed in prostate in
both normal human tissues and prostate cancers [14]. We,
thus, examined DC mediated antibody production against
hPSGR. To test immunized serum for reactivity to native
extracellular domains of hPSGR, a ﬂow cytometry analysis
using LNCaP cells, which endogenously express PSGR [14],
was conducted. The LNCaP cells were positively stained
with sera collected from immunized mice (Figure 3(a)).
Hydrodynamic booster immunization alone failed to induce
a signiﬁcant antibody response against hPSGR in ﬂow
cytometry analysis (data not shown). By immunoﬂuores-
cent staining, PSGR expression was speciﬁcally detected
on the cell surface of LNCaP cells (Figure 3(b)). The cell
surface speciﬁc staining even without cell permieabilization
treatment (Figure 3(b)) suggested anti-PSGR serum in DC
immunization reacted with extracelluar domain of PSGR
as well as ﬂow cytometry analysis. Taken together, these
observations indicate that DC immunization is eﬀective in
inducing antibody production against PSGR, in addition to
STEAP family proteins.
3.4. The Antigen Speciﬁc IgG1/2a Ratio in DC Immunization.
To further characterize the antibody response, we deter-
mined IgG1/2a ratio of anti-HA antibody. The ratio of
IgG1/2a represents the balance of Th2/Th1 response. The
anti-HA speciﬁc immunological response evoked by DC
immunization was shown to be Th2 dominant because the
ratioofIgG1/2ainDCimmunizationwas8.75ataverageand
anti-HA IgG1 was more abundant than IgG2a (Figure 4).
The ratio of IgG1/2a in DC immunization was higher
than hydrodynamics method (average of 4.17), although the
diﬀerence was not statistically signiﬁcant.
4. Discussion
In this study, we investigated whether DCs as immuno-
gens elicited antibody production against multiple-trans-
membrane proteins expressed in human prostate cancer
cells. BM-DCs stably expressing membrane proteins were
used to immunize mice. Antigen speciﬁc antibodies reactive
with native extracellular domains of membrane proteins
were detected. Previous studies demonstrated that immu-
nization of mice with antigen-pulsed DCs resulted in
eﬃcient induction of antibody response [20]. Accordingly,
our results underline the utility of DC immunization in the
induction of antibody response against the external domains
of membrane tumor antigens that might be useful for devel-
opment of antibody mediated treatment of cancer diseases.
The priming immunization with DCs was very eﬀective,
whereas plasmid-based immunization using hydrodynamic
delivery alone was not suﬃcient to stimulate antibody
generation,althoughhydrodynamicswasaneﬃcientmethod
for booster immunizations (Figures 1 and 2). Moreover,
DCsexertedsuperioractivityinantibodyproductionrelative
to BALB/C 3T3 ﬁbroblasts in HA immunization (data not
shown). These observations suggest that DCs possess strong
priming activity to induce antibody production. In general,
DCs are particularly known to induce Th1 immune response
because of their ability to initiate adaptive cellular immune
response through production of high amounts of IL-12.
However, the high IgG1/2a ratio obtained following DC
immunization indicated their potential eﬀect in stimulation
of antibody production as well. Actually, because HA
antigen is highly antigenic, hydrodynamic immunization
signiﬁcantly could induce anti-HA humoral responses, but
IgG1/2aratioinDCimmunizationwashigherthanhydrody-
namic immunization, suggesting that DC immunization can
stimulate antibody response with Th2 proﬁle. This strong
immune response is particularly needed when using less
immunogenic proteins such as STEAPs, which are highly
homologous between human and mice.
The STEAP family (STEAP1-4) consists of a unique
group of proteins: other proteins homologous to the STEAP
family do not exist in higher mammals. The STEAP family
proteins share a high degree of homology in amino acid
sequence, but there may be functional diﬀerences between
STEAP1 and STEAP4. STEAP1 is largely lacking a cytoplas-
m i cN - t e r m i n a lt a i lh o m o l o g o u st ob a c t e r i a la n da r c h a e a l
FNO oxidoreductase, diﬀerent from other STEAP proteins.
STEAP4exhibitsastrongironreductaseactivity,butSTEAP1
showed no such activity [21]. In fact, coexpression of
STEAP1andSTEAP4mayoccurinsomehumannormaland
malignant tissues. The interplay between STEAP members
to modulate their biological functions remains elusive. An
antibody-based analysis will be critical for understanding
STEAP function and the DC immunization protocol used in
this study can provide such antibodies.
Recent work demonstrated that loss of STEAP4 led to
metabolic syndrome in mice [22]. We found that STEAP48 Journal of Biomedicine and Biotechnology
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Figure 3: hPSGR immunization. (a) hPSGR expression in LNCaP cells using ﬂow cytometry analysis. Solid line: anti-PSGR serum. Dashed
line: preimmune serum. (b) Immunoﬂuorescent staining of LNCaP cells using anti-PSGR serum. Arrow indicates a stained cell. Scale bar =
20μm.
expression was restricted to a small population of LNCaP
cells. The characterization of these cells remains to be con-
ducted. A ﬂow cytometry analysis using anti-STEAP4 serum
did not detect expression of STEAP4 in androgen indepen-
dent DU145 cells (data not shown), which is consistent with
previous results [16]. We are currently investigating whether
STEAP4 function is involved in tumor progression. The
monoclonal antibodies generated in this study were demon-
strated to bind to the extracellular domains of hSTEAP4,
suggesting that these antibodies could be functional to
promote or inhibit the functions of STEAP4. Moreover, they
could exert eﬀector activities such as complement dependent
cytotoxicity or antibody dependent cellular cytotoxicity. The
monoclonal antibodies will be useful in these studies as well
as in research on a role of STEAP4 in metabolic syndrome in
mice and human.
PSGR expression is highly speciﬁc in normal prostate
and prostate cancers, which makes it a very attractive
target for antibody mediated therapy against prostate cancer.
Numerous GPCRs, in addition to PSGR, are expressed
in tumor tissues. DC immunization successfully induced
antibody production against hPSGR, in this study. Using DC
immunization, a variety of antibodies reactive with GPCRs
can be prepared and can contribute to development of
antitumor therapies.
The DC-mediated immunization protocol developed in
this study is simple, and eﬃciently induced antibody pro-
duction against the extracellular domains of several human
multipletransmembraneproteinsinmice.Wealsogenerated
monoclonal antibodies from an immunized mouse. The
development of larger scale DC culture protocols, or more
eﬃcient gene delivery into DCs will be important to improve
immunization results. Furthermore, genetic manipulation of
DC to confer immunomodulatory functions may be critical,
depending on the immune responses evoked by particular
antigens. We are further developing DC immunizationJournal of Biomedicine and Biotechnology 9
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Figure 4: The ratio of anti-HA speciﬁc IgG1/2a in DC immuniza-
tion. The BM-DCs expressing HA were injected into mice (n = 5).
For control, hydrodynamic injection of pCAGGS-HA was carried
out (n = 4). After booster immunization, the ratio of anti-HA
speciﬁc IgG1/2a was determined using ﬂow cytomery analysis. Data
represent means ± SE of each group.
protocols to generate monoclonal antibodies that speciﬁcally
react with cancer stem cells, or highly metastatic cancer
cells, which will be useful for novel anticancer therapeutic
strategies.
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